The most recently approved therapies for SLE include the monoclonal antibody against BAFF and targeting type I IFN through a receptor monoclonal antibody that blocks the action of type I IFNs (IFN-α and IFN-β) (55). Here, IFNB1 is linked to systemic lupus erythematosus.